ACHFF (Arch Biopartners) Loans Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Arch Biopartners Loans Receivable?

Arch Biopartners's Loans Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Arch Biopartners Loans Receivable Historical Data

The historical data trend for Arch Biopartners's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Loans Receivable Chart

Arch Biopartners Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Loans Receivable

Get a 7-Day Free Trial

Arch Biopartners Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24	Dec24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Arch Biopartners Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Arch Biopartners Loans Receivable Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

ARCH:Canada

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.